Rakovina Therapeutics Comments on $500 Billion AI Infrastructure Investment and Its Implications for Healthcare Innovation
22 janv. 2025 07h30 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront of AI-driven drug discovery, yesterday commented...
Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI
13 janv. 2025 08h30 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel...
Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation
06 janv. 2025 08h30 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel...
Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week
03 janv. 2025 16h30 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics, Inc. (TSX: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel...
Rakovina Therapeutics: Reflecting on 2024 Success and Building Momentum for a Transformative 2025
19 déc. 2024 07h55 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) a biopharmaceutical company focused on the development of new...
Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
17 déc. 2024 21h55 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that in accordance with the terms of an indenture...
Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement
13 déc. 2024 18h50 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”, “Rakovina”, or “Rakovina Therapeutics”) a biopharmaceutical company committed to...
Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit
03 déc. 2024 07h35 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer...
Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million
02 déc. 2024 18h22 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing...
Rakovina Therapeutics Announces 2024 Q3 Financial Results and Provides Corporate Update
29 nov. 2024 20h40 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...